Modulation or/and inhibition of immune checkpoints receptors have become the subject of growing interest for new therapies in immuno-oncology. Immune check point receptors expressed by immune cells can have either inhibitory or stimulatory functions.
Two strategies for immunotherapy have been investigated:
- Inhibition of checkpoint blockade to restore T cell activity,
- Activation of stimulatory checkpoints to stimulate T cell activity.
Assessing the effect of a drug candidates such as small molecules or biologics on the immune checkpoint interactions is now a major challenge for research and drug discovery.